HYTN Receives Opening Order and Import Permits from the UK's 4C Labs, Prepares Products for Export
HYTN Innovations has received initial orders and import permits from the UK's 4C Labs, enabling the company to begin exporting cannabis-based pharmaceuticals to the United Kingdom. The company has completed registration on the UK's National Drugs Control System (NDS), allowing transactions with licensed UK companies. The first shipment will be manufactured under Good Manufacturing Practices (GMP) standards, marking HYTN's transition from a domestic to international cannabis company.
HYTN Innovations ha ricevuto ordini iniziali e permessi di importazione dai 4C Labs del Regno Unito, che consentono all'azienda di iniziare a esportare farmaci a base di cannabis verso il Regno Unito. L'azienda ha completato la registrazione nel Sistema Nazionale di Controllo dei Farmaci (NDS) del Regno Unito, permettendo transazioni con aziende britanniche autorizzate. La prima spedizione sarà realizzata secondo gli Standard di Buona Pratica di Fabbricazione (GMP), segnando la transizione di HYTN da un'azienda domestica a un'azienda internazionale nel settore della cannabis.
HYTN Innovations ha recibido pedidos iniciales y permisos de importación de los 4C Labs del Reino Unido, lo que permite a la empresa comenzar a exportar productos farmacéuticos a base de cannabis al Reino Unido. La empresa ha completado el registro en el Sistema Nacional de Control de Drogas (NDS) del Reino Unido, lo que permite transacciones con empresas británicas autorizadas. El primer envío se fabricará bajo los Buenas Prácticas de Fabricación (GMP), marcando la transición de HYTN de una empresa nacional a una empresa internacional de cannabis.
HYTN Innovations는 영국의 4C Labs로부터 초기 주문과 수입 허가를 받아 영국으로 대마초 기반의 의약품 수출을 시작할 수 있게 되었습니다. 이 회사는 영국의 국가 약물 관리 시스템(NDS)에 등록을 완료하여 라이센스가 부여된 영국 회사와 거래할 수 있게 되었습니다. 첫 번째 배송은 우수 제조 관행(GMP) 기준에 따라 제조되어 HYTN이 국내 기업에서 국제 대마초 기업으로 전환하는 시점을 알리게 됩니다.
HYTN Innovations a reçu des commandes initiales et des permis d'importation des 4C Labs du Royaume-Uni, permettant à l'entreprise de commencer à exporter des médicaments à base de cannabis vers le Royaume-Uni. L'entreprise a complété son enregistrement dans le Système National de Contrôle des Drogues (NDS) du Royaume-Uni, ce qui permet des transactions avec des entreprises britanniques autorisées. Le premier envoi sera fabriqué selon les Bonnes Pratiques de Fabrication (BPF), marquant la transition de HYTN d'une entreprise nationale à une entreprise internationale spécialisée dans le cannabis.
HYTN Innovations hat erste Bestellungen und Importgenehmigungen von den 4C Labs im Vereinigten Königreich erhalten, was es dem Unternehmen ermöglicht, mit dem Export von cannabisbasierten Arzneimitteln in das Vereinigte Königreich zu beginnen. Das Unternehmen hat die Registrierung im Nationalen Drogenkontrollsystem (NDS) des Vereinigten Königreichs abgeschlossen, was Transaktionen mit lizenzierten britischen Unternehmen erlaubt. Die erste Lieferung wird nach den guten Herstellungspraktiken (GMP) Standards hergestellt, was den Übergang von HYTN von einem nationalen zu einem internationalen Cannabisunternehmen markiert.
- Secured initial orders from UK market
- Obtained UK import permits
- Completed registration on UK's National Drugs Control System
- Gained ability to export cannabis pharmaceuticals internationally
- Established partnership with 4C Labs for UK distribution
- None.
VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce the receipt of initial orders and import permits from the UK's 4C Labs, marking a significant milestone in their partnership. This achievement allows HYTN to begin exporting premium cannabis-based pharmaceuticals to the UK under the company's recently established agreements. The first shipment, manufactured by HYTN under Good Manufacturing Practices (GMP) standards, reflects HYTN's commitment to expanding its global reach and providing high-quality cannabis products to international markets.
“We are thrilled to take this next step with 4C Labs,” stated Elliot McKerr, Chief Executive Officer of HYTN. “This milestone underscores the strength of our collaboration and signals the shift from a domestic to international cannabis company.”
HYTN notes the receipt of this initial order and importation permits required the company to obtain registration on the UK's National Drugs Control System (NDS) which has since been completed. Now registered, HYTN is permitted to transact with UK companies that hold a UK domestic controlled drug or domestic drug precursor licence.
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company that specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The Company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.
About 4C LABS Ltd.
4C LABS is a Canadian based Medical Cannabis company which is building a vertically integrated, quality-driven infrastructure for procuring and delivering premium medical cannabis products to the UK, EU and other international regulated markets.
4C LABS focuses on launching products in regulated markets with an additional focus on research and development of new and innovative plant based therapeutic finished product forms that can be introduced to the 4C catalogue.
About Good Manufacturing Practices (GMP)
Good manufacturing practice guidelines provide guidance for manufacturing, testing, and quality assurance to ensure that a manufactured product is safe for human consumption or use. Many countries have legislated that manufacturers follow GMP procedures and create their own GMP guidelines that correspond with their legislation.
For more information contact:
Elliot McKerr
Chief Executive Officer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
investments@hytn.life
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.
Certain information contained herein may constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including, but not limited to, statements regarding the Company’s expanded abilities to export its products globally, including to the UK. Factors that could cause actual results to vary from forward-looking statements or may affect the operations, performance, development, and results of the Company’s business include, among other things: the Company's failure to generate sufficient cash flow from operations to meet its current and future obligations; the Company's failure to access sources of debt and equity capital; changes to the regulatory framework within which the Company operates; competitive factors, pricing pressures, and supply and demand in the Company’s industry; and general economic and business conditions. Any statements that are not statements of historical fact are deemed to be forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether because of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note.
FAQ
What permits has HYTN (HYTNF) received for UK cannabis exports?
When did HYTN (HYTNF) receive its first UK order?
What manufacturing standards will HYTN (HYTNF) use for UK exports?
Who is HYTN's (HYTNF) UK distribution partner?
